Oritavancin exhibited in vitro activity against 169 strains of vancomycin-susceptible, methicillin-resistant Staphylococcus aureus (MRSA) with MICs ranging from 0.03 to 1 g/ml and against vancomycin-intermediate MRSA (VISA; n ‫؍‬ 29), heterogeneous vancomycin-intermediate MRSA (hVISA; n ‫؍‬ 5), and vancomycin-resistant MRSA (n ‫؍‬ 5) strains, with MICs ranging from 0.12 to 4 g/ml. For 10 MRSA isolates comprising 5 VISA and 5 hVISA strains, synergy between oritavancin and gentamicin, linezolid, or rifampin was observed against most of the strains tested using a time-kill method.
M
ethicillin-resistant S. aureus (MRSA) is a global concern, with the majority of strains (and some methicillin-susceptible [MSSA] strains) also exhibiting resistance to currently available quinolones. Furthermore, the appearance and rapid spread of community-associated MRSA in the United States pose clinical challenges. Treatment of MRSA strains in certain types of infections, such as osteomyelitis and bacteremia, with glycopeptides has undoubtedly increased selective pressure, leading to nonsusceptible organisms such as heterogeneous vancomycin-intermediate S. aureus (hVISA), vancomycin-intermediate S. aureus (VISA) (1, 2) , and vancomycin-resistant S. aureus (VRSA) (3) .
The mechanism of glycopeptide resistance in VISA strains is due to cell wall thickening; some of these strains also exhibit reduced susceptibility to daptomycin (4, 5) . Among Hershey MRSA strains isolated between August 2006 and February 2007 from patients that had received prior vancomycin therapy, we determined the incidence of hVISA and VISA to be approximately 1% (1) .
Oritavancin, a lipoglycopeptide in late clinical development, has potent in vitro activity against MRSA (6, 7) . Synergy between oritavancin and gentamicin, linezolid, or rifampin against 1 methicillin-susceptible strain and 2 MRSA strains (1 VISA and 1 VRSA strain) has been described (8) . In this study, we examined the in vitro activities of oritavancin and comparators against 200 recent MRSA isolates. Furthermore, we used time-kill studies to assess synergy between oritavancin and gentamicin, linezolid, or rifampin against 5 VISA and 5 hVISA isolates.
Two hundred three recent MRSA isolates were used in this study, including 127 community-associated organisms (MRSA is defined as community-associated if the MRSA-positive specimen was obtained outside a hospital setting or within 2 days of hospital admission) and 42 hospital-associated organisms isolated from 25 geographically diverse regions in the United States. Two hVISA, 4 VISA, and 1 VRSA isolate were from the Hershey Medical Center. Four VRSA, one hVISA, and 22 VISA isolates were obtained from the Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA) (2) . Two hVISA and 127 community-associated MRSA isolates were obtained from JMI Laboratories (Liberty City, IA). Ten S. aureus strains (5 VISA and 5 hVISA strains) were tested in the time-kill studies. For synergy time-kill testing, which was performed according to CLSI guidelines and as previously described (4, 9, 10), oritavancin was combined with gentamicin, linezolid, or rifampin. Kill kinetics of each drug alone were determined by incubating an initial inoculum of 5 ϫ 10 5 to 5 ϫ 10 6 CFU/ml with drug concentrations at the MIC (see Table 2 for isolates' initial MICs used for time-kill testing) and 2 dilutions above (2ϫ and 4ϫ MIC) and 3 dilutions below the MIC (1/2ϫ, 1/4ϫ, and 1/8ϫ MIC). Viability counts were performed at 0, 3, 6, 12, and 24 h of incubation at 35°C in a shaking water bath by plating undiluted and 10-fold serially diluted samples. Concentrations of drugs used in synergy time-kill studies were selected such that one of the two drugs yielded a growth curve similar to that of the drug-free control, while the other drug may have been more active. To prevent drug carryover, aliquots were added to an equal volume of a 25-mg/ml sterile activated charcoal suspension (in 0.9% saline) and then serially diluted (11) . Synergy was defined as a Ն2-log 10 decrease in CFU/ml between the combination and its most active constituent after 3, 6, 12, and 24 h, with a decrease of Ն2 log 10 CFU/ml between the number of surviving organisms and the starting inoculum. Bacteriostatic and bactericidal activities were defined as Ͻ3-log 10 and Ն3-log 10 reductions in CFU/ml, respectively, relative to the starting inoculum. The definitions of synergy and bacteriostatic and bactericidal activities were from the Antimicrobial Agents and Chemotherapy instructions to authors regarding in vitro susceptibility tests (12) . Drug panels in microtiter trays for susceptibility tests were provided by The Medicines Company (Parsippany, NJ). Broth microdilution and macrodilution MICs were determined in cationadjusted Muller-Hinton broth (CAMHB; BD Diagnostics, Sparks, MD) according to CLSI guidelines (13, 14) ; MICs of quality control strains were verified during each determination. For all testing involving oritavancin, CAMHB was supplemented with 0.002% polysorbate-80 (Sigma-Aldrich).
The MIC ranges and MIC 50 and MIC 90 for all strains tested are presented in Table 1 . Oritavancin showed potent activity against 127 community-and 42 hospital-associated vancomycin-susceptible MRSA strains with MICs ranging from 0.03 to 1 g/ml, and MIC 50 and MIC 90 values of 0.12 and 0.25 g/ml, respectively. An identical MIC 90 for oritavancin (0.25 g/ml) was obtained in a prior study of community-associated MRSA from the New York/ New Jersey area (7). Against 5 hVISA and 24 VISA strains, oritavancin had an MIC range of 0.12 to 2 g/ml, with MIC 50 and MIC 90 values of 0.5 and 1 g/ml. When tested against five VRSA strains, oritavancin had an MIC range of 0.12 to 1 g/ml. Seventeen of the 24 VISA strains were nonsusceptible to daptomycin (MIC Ͼ 1 g/ml). Previous reports (5, 15) confirmed higher daptomycin MICs against VISA strains and the propensity of daptomycin therapy to select for such phenotypes. Using CLSI breakpoints (14), 13 (6%), 2 (1.0%), and 12 (6%) of all tested strains were resistant to trimethoprim-sulfamethoxazole, minocycline, and rifampin, respectively.
MIC results by broth micro-and macrodilutions are presented in Table 2 . Broth macrodilution MICs were similar to those obtained by broth microdilution. Two strains with gentamicin MICs of Ͼ1,024 g/ml and one strain with a rifampin MIC of Ͼ1,024 g/ml were not tested in synergy time-kill assays in combination with these agents. Also, no VISA isolate from an endocarditis patient treated with daptomycin was tested in the synergy study. Figures 1 and 2 are graphic representations of synergy observed when oritavancin was combined with each of the tested antimicrobials at subinhibitory concentrations against an hVISA and a VISA strain, respectively. With the combination of oritavancin and gentamicin, synergy was observed against 2 of the 8 strains tested by 3 h (Table 3) . By 6 h, synergy was observed against 7 strains. Although synergy was observed for all 8 strains by 12 and 24 h, for 3 of these strains it required concentrations of gentamicin considered too high to be clinically achievable (64 to 128 g/ml).
The combination of oritavancin and linezolid yielded synergy against all 10 strains tested; synergy was observed in 2 strains by 6 h, and the other 8 strains by 12 h (Table 3) . For all 10 strains, the linezolid concentration used in the combination was below the CLSI susceptibility breakpoint (Յ4 g/ml) (14) .
Oritavancin and rifampin in combination exhibited synergy against 7 of 9 strains tested by 24 h, with synergy observed against 2 and 4 strains by 3 h and 6 h, respectively (Table 3) . Against the 7 strains, the rifampin concentration used in the combination was below the CLSI susceptibility breakpoint (Յ1 g/ml) (14) .
In summary, oritavancin showed excellent in vitro potency by MIC against all MRSA strains tested, including community-and hospital-associated and vancomycin-susceptible and non-vancomycin-susceptible strains. Only 3 of all 203 strains tested had oritavancin MICs of Ͼ1 g/l, and all 3 were VISA isolates. Oritavancin also exhibited bactericidal activity against the 5 hVISA and 5 VISA (oritavancin MICs ranging from 0.12 to 2 g/l) strains tested by time-kill assays in this study. A similar bactericidal activity of oritavancin against VISA strains has been described previously (8, 16) . Synergistic activity of oritavancin in combination with gentamicin or linezolid was observed in all the tested strains. For the combination of oritavancin and rifampin, synergy was observed in 7 of the 9 strains tested. No antagonism was found with any drug combination. Oritavancin concentrations observed in this synergy study were within concentrations predicted to be clinically achievable following a single 1,200-mg dose (17, 18) . The marked cross-resistance between oritavancin and daptomycin (19, 20) in non-daptomycin-susceptible VISA isolates was not evaluated in this study.
Antimicrobial combinations that include oritavancin have potential to improve antimicrobial activity against VISA and hVISA isolates. 
